404. Hargrave DR, et al. (2022) J Clin Oncol, 40: 2009. 405. Ahcene Djaballah S, et al. (2022) Am Soc Clin Oncol Educ Book, 42: 1. 406. Strickler JH, et al. (2023) Lancet Oncol, 24: 496. 407. de Botton S, et al. (2023) Blood Adv, 7: 3117. 408. Yanada M, et al. (2005) Leukemia, 19: 1345. 409. Erba HP, et al. (2023) Lancet, 401: 1571. 410. Verstovsek S, et al. (2018) Ann Oncol, 29: 1880. 411. Alu A, et al. (2022) J Hematol Oncol, 15: 138. 412. Zhang J, et al. (2022) Biomark Res, 10: 17. 413. Sengupta R, et al. (2020) Cancer Epidemiol Biomarkers Prev, 29: 1843. 414. Brown JR, et al. (2023) N Engl J Med, 388: 319. 415. de Bono J, et al. (2020) N Engl J Med, 382: 2091. 416. Agarwal N, et al. (2023) Lancet, 402: 291. 417. Hiam-Galvez KJ, et al. (2021) Nat Rev Cancer, 21: 345. 418. Mishra AK, et al. (2022) Diseases, 10. 419. McCarthy EF (2006) Iowa Orthop J, 26: 154. 420. Kaufmann SHE (2019) Front Immunol, 10: 684. 421. Waldman AD, et al. (2020) Nat Rev Immunol, 20: 651. 422. Goebeler ME, et al. (2020) Nat Rev Clin Oncol, 17: 418. 423. Marin-Acevedo JA, et al. (2021) J Hematol Oncol, 14: 45. 424. Pardoll DM (2012) Nat Immunol, 13: 1129. 425. Kahlon N, et al. (2022) JAMA Netw Open, 5: e2245269. 426. Garon EB, et al. (2019) J Clin Oncol, 37: 2518. 427. Pala L, et al. (2022) JAMA Netw Open, 5: e2226252. 428. Zhuo Y, et al. Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. In: Hoshida Y, editor. Hepatocellular Carcinoma: Translational Precision Medicine Approaches. Cham (CH)2019. p 53. 429. Abou-Alfa GK, et al. (2022) NEJM Evidence, 1: EVIDoa2100070. 430. Johnson ML, et al. (2023) J Clin Oncol, 41: 1213. 431. Oh D-Y, et al. (2022) NEJM Evidence, 1: EVIDoa2200015. 432. Kelley RK, et al. (2023) Lancet, 401: 1853. 433. Rosenberg JE, et al. (2023) J Clin Oncol, 41: 4505. 434. Challita-Eid PM, et al. (2016) Cancer Res, 76: 3003. 435. Paulson KG, et al. (2018) J Am Acad Dermatol, 78: 457. 436. Topalian SL, et al. (2019) JAMA Oncol, 5: 1411. 437. Lamba N, et al. (2022) JAMA Netw Open, 5: e2225459. 438. Voruganti T, et al. (2023) JAMA Oncol, 9: 334. 439. LeBlanc ML, et al. (2023) J Clin Oncol, 41: LBA4. 440. Schmid P, et al. (2020) N Engl J Med, 382: 810. 441. Altorki NK, et al. (2021) Lancet Oncol, 22: 824. 442. Carthon BC, et al. (2010) Clin Cancer Res, 16: 2861. 443. Liakou CI, et al. (2008) Proc Natl Acad Sci U S A, 105: 14987. 444. Ludford K, et al. (2023) J Clin Oncol, 41: 2181. 445. Cercek A, et al. (2022) N Engl J Med, 386: 2363. 446. Patel S, et al. (2022) Annals of Oncology, 33: S1408. 447. Gross ND, et al. (2022) N Engl J Med, 387: 1557. 448. Rohaan MW, et al. (2019) Virchows Arch, 474: 449. 449. Mitra A, et al. (2023) Front Immunol, 14: 1188049. 450. Brentjens RJ, et al. (2011) Blood, 118: 4817. 451. Porter DL, et al. (2011) N Engl J Med, 365: 725. 452. Grupp SA, et al. (2013) N Engl J Med, 368: 1509. 453. Maude SL, et al. (2018) N Engl J Med, 378: 439. 454. Laetsch TW, et al. (2023) J Clin Oncol, 41: 1664. 455. Dana H, et al. (2021) Acta Pharm Sin B, 11: 1129. 456. Westin JR, et al. (2023) N Engl J Med. 457. Liu C, et al. (2021) Adv Sci (Weinh), 8: e2004433. 458. Conlon KC, et al. (2019) J Interferon Cytokine Res, 39: 6. 459. Golomb HM, et al. (1986) J Clin Oncol, 4: 900. 460. McDermott DF, et al. (2006) Semin Oncol, 33: 583. 461. Xue D, et al. (2021) Antib Ther, 4: 123. 462. Mond HG, et al. (1981) Pacing Clin Electrophysiol, 4: 304. 463. Bree KK, et al. (2021) Hematol Oncol Clin North Am, 35: 513. 464. Boorjian SA, et al. (2021) Lancet Oncol, 22: 107. 465. Lobo N, et al. (2021) Nat Rev Urol, 18: 611. 466. Lee A (2023) Drugs, 83: 353. 467. Melani C, et al. (2023) Lancet Haematol, 10: e346. 468. Baselga J, et al. (2015) Clin Cancer Res, 21: S1. 469. Tian Z, et al. (2021) J Hematol Oncol, 14: 75. 470. Moreau P, et al. (2022) N Engl J Med, 387: 495. 471. Leslie M (2023) Cancer Discov, 13: OF1. 472. Budde LE, et al. (2022) Lancet Oncol, 23: 1055. AACR Cancer Progress Report 2023 References 176
RkJQdWJsaXNoZXIy NTkzMzk=